CRISPR Screen Contributes to Novel Target Discovery in Prostate Cancer.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
26 Nov 2021
Historique:
received: 30 10 2021
revised: 25 11 2021
accepted: 25 11 2021
entrez: 10 12 2021
pubmed: 11 12 2021
medline: 21 12 2021
Statut: epublish

Résumé

Prostate cancer (PCa) is one of the common malignancies in male adults. Recent advances in omics technology, especially in next-generation sequencing, have increased the opportunity to identify genes that correlate with cancer diseases, including PCa. In addition, a genetic screen based on CRISPR/Cas9 technology has elucidated the mechanisms of cancer progression and drug resistance, which in turn has enabled the discovery of new targets as potential genes for new therapeutic targets. In the era of precision medicine, such knowledge is crucial for clinicians in their decision-making regarding patient treatment. In this review, we focus on how CRISPR screen for PCa performed to date has contributed to the identification of biologically critical and clinically relevant target genes.

Identifiants

pubmed: 34884583
pii: ijms222312777
doi: 10.3390/ijms222312777
pmc: PMC8658029
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Biomarkers, Tumor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Références

Oncogene. 2019 Apr;38(14):2451-2463
pubmed: 30532030
Nat Protoc. 2013 Nov;8(11):2180-96
pubmed: 24136345
Cancer Discov. 2016 Aug;6(8):914-29
pubmed: 27260156
Cancer Lett. 2021 Apr 1;502:58-70
pubmed: 33429005
Nat Genet. 2017 Feb;49(2):193-203
pubmed: 27992415
Nat Protoc. 2017 Apr;12(4):828-863
pubmed: 28333914
Int J Urol. 2018 Mar;25(3):220-231
pubmed: 29266472
Cell. 2015 May 21;161(5):1215-1228
pubmed: 26000489
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20380-5
pubmed: 19091943
Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25186-25195
pubmed: 31727847
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36):
pubmed: 34475205
Clin Cancer Res. 2014 Jun 15;20(12):3211-21
pubmed: 24771642
Theranostics. 2021 Jan 25;11(8):3624-3641
pubmed: 33664852
Lancet. 2016 Jan 2;387(10013):70-82
pubmed: 26074382
Front Cell Dev Biol. 2021 Jan 26;8:616332
pubmed: 33575255
Genome Res. 2015 Aug;25(8):1147-57
pubmed: 26063738
Nat Rev Genet. 2017 Oct;18(10):613-623
pubmed: 28649135
Oncologist. 2013;18(12):1248-55
pubmed: 24258613
F1000Res. 2014 Apr 24;3:95
pubmed: 24860646
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
Eur Urol. 2021 Apr;79(4):442-445
pubmed: 33012578
JAMA Oncol. 2017 Jan 1;3(1):58-66
pubmed: 27584578
Nature. 2004 Mar 25;428(6981):431-7
pubmed: 15042092
Cancer Res. 2012 Mar 15;72(6):1494-503
pubmed: 22266222
Nature. 2015 Jan 29;517(7536):583-8
pubmed: 25494202
Science. 2014 Jan 3;343(6166):84-87
pubmed: 24336571
Eur Urol. 2021 Feb;79(2):200-211
pubmed: 33176972
Lancet Oncol. 2017 Jul;18(7):e376
pubmed: 28602780
Bioinformatics. 2016 Feb 15;32(4):632-4
pubmed: 26508755
Science. 2016 Aug 26;353(6302):933-6
pubmed: 27540007
Nat Biotechnol. 2016 Feb;34(2):184-191
pubmed: 26780180
Sci Rep. 2017 Nov 20;7(1):15854
pubmed: 29158538
Nature. 2016 Jul 7;535(7610):159-63
pubmed: 27383987
Mol Cancer. 2021 Aug 5;20(1):100
pubmed: 34353330
FEBS J. 2016 Sep;283(17):3170-80
pubmed: 27250066
Proc Natl Acad Sci U S A. 2017 Jun 27;114(26):E5207-E5215
pubmed: 28611215
Nature. 2018 Jul;559(7713):285-289
pubmed: 29973717
EMBO J. 2011 May 20;30(13):2719-33
pubmed: 21602788
Cell Rep. 2016 Oct 18;17(4):1193-1205
pubmed: 27760321
Clin Cancer Res. 2017 Jun 15;23(12):3097-3108
pubmed: 27993965
Science. 2016 Mar 11;351(6278):1214-8
pubmed: 26912360
Cell Death Dis. 2021 Jul 27;12(8):740
pubmed: 34315855
Gut. 2021 Apr;70(4):743-760
pubmed: 32873698
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
N Engl J Med. 2019 Dec 26;381(26):2506-2518
pubmed: 31566937
Nat Chem Biol. 2016 May;12(5):361-6
pubmed: 27018887
Cell. 2017 Feb 23;168(5):890-903.e15
pubmed: 28162770
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Nat Commun. 2018 Oct 22;9(1):4394
pubmed: 30349055
Genome Biol. 2015 Dec 16;16:281
pubmed: 26673418
Ann Oncol. 2016 Apr;27 Suppl 1:i40-i44
pubmed: 27141070
Cell. 2021 Jan 7;184(1):76-91.e13
pubmed: 33147444
Genome Biol. 2014;15(12):554
pubmed: 25476604
Nat Protoc. 2019 Mar;14(3):756-780
pubmed: 30710114
Lancet Oncol. 2021 Sep;22(9):1250-1264
pubmed: 34388386
Nat Methods. 2014 Aug;11(8):783-784
pubmed: 25075903
Cell. 2015 Jul 30;162(3):675-86
pubmed: 26189680
Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):
pubmed: 29311132
Cell. 2013 Jul 18;154(2):442-51
pubmed: 23849981
Cell. 2015 Dec 3;163(6):1515-26
pubmed: 26627737
Elife. 2019 Dec 19;8:
pubmed: 31855178
J Clin Invest. 2018 Jul 2;128(7):2979-2995
pubmed: 29863497
Eur Urol. 2016 Jun;69(6):992-5
pubmed: 26724258
Nat Commun. 2021 Jul 29;12(1):4601
pubmed: 34326322
Sci Transl Med. 2014 Sep 17;6(254):254ra125
pubmed: 25232177
Br J Cancer. 2021 Apr;124(9):1533-1539
pubmed: 33674736
J Clin Invest. 2018 Jan 2;128(1):446-462
pubmed: 29202477
Clin Cancer Res. 2015 Jun 1;21(11):2480-6
pubmed: 25739672
Genome Med. 2019 Aug 22;11(1):52
pubmed: 31439014
Nat Rev Microbiol. 2017 Jun;15(6):351-364
pubmed: 28420884
Cell. 2016 Apr 7;165(2):317-30
pubmed: 27058664
Nat Genet. 2017 Dec;49(12):1779-1784
pubmed: 29083409
Nature. 2013 Oct 17;502(7471):333-339
pubmed: 24132290
Cell. 2017 Jul 27;170(3):577-592.e10
pubmed: 28753431
J Clin Invest. 2018 Oct 1;128(10):4441-4453
pubmed: 30179225
Nat Commun. 2020 Jul 24;11(1):3726
pubmed: 32709856
Cancer Discov. 2016 Aug;6(8):900-13
pubmed: 27260157
Genome Biol. 2015 Nov 27;16:260
pubmed: 26612492
Cell. 2014 Oct 23;159(3):647-61
pubmed: 25307932
Cell. 2017 Jul 27;170(3):564-576.e16
pubmed: 28753430
Science. 2014 Nov 28;346(6213):1258096
pubmed: 25430774
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
Sci Rep. 2021 Jul 1;11(1):13683
pubmed: 34211036
J Clin Oncol. 2017 Jun 1;35(16):1778-1785
pubmed: 28388291
Nature. 2013 Dec 5;504(7478):138-42
pubmed: 24185007
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1521-6
pubmed: 24434559
Nat Biotechnol. 2013 Sep;31(9):833-8
pubmed: 23907171
J Clin Oncol. 2020 Nov 10;38(32):3763-3772
pubmed: 32795228
Science. 2016 Apr 1;352(6281):54-61
pubmed: 26917594
BMC Bioinformatics. 2016 Apr 16;17:164
pubmed: 27083490
Int J Mol Sci. 2020 Nov 12;21(22):
pubmed: 33198356
Clin Cancer Res. 2019 May 1;25(9):2708-2716
pubmed: 30796035
Eur Urol. 2014 Sep;66(3):468-74
pubmed: 24412228
Nat Genet. 2012 May 20;44(6):685-9
pubmed: 22610119
Nat Rev Urol. 2019 Nov;16(11):645-654
pubmed: 31591549
Eur Urol. 2019 Jan;75(1):88-99
pubmed: 29673712

Auteurs

Takuya Tsujino (T)

Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
Division of Urology, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Kazumasa Komura (K)

Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.
Translational Research Program, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.

Teruo Inamoto (T)

Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.

Haruhito Azuma (H)

Department of Urology, Osaka Medical and Pharmaceutical University, Osaka 569-8686, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH